淋巴瘤相关噬血细胞性淋巴组织细胞增多症(LA-HLH):一项范围综述揭示预后不良淋巴瘤亚组的临床与诊断模式
该范围综述通过检索PubMed(MEDLINE数据库)系统分析已发表文献,共纳入132篇文章、542例淋巴瘤相关噬血细胞性淋巴组织细胞增多症(LA-HLH)患者。患者中位年龄60岁,男性占62.7%,B细胞和T细胞非霍奇金淋巴瘤分别占45.6%和45.2%,霍奇金淋巴瘤占8.9%。91.6%的患者为Ann-Arbor III-IV期,61.5%存在骨髓浸润,可溶性CD25中位水平为10,000 U/ml,超过10,000 U/ml提示30天生存和总生存预后不良,66.8%的患者在中位5.1个月后死亡。
要点
- LA-HLH患者中位年龄60岁,男性占62.7%,B细胞与T细胞非霍奇金淋巴瘤比例相近。
- 91.6%的患者为Ann-Arbor III-IV期,61.5%存在骨髓浸润。
- 可溶性CD25中位10,000 U/ml,超过10,000 U/ml提示30天和总生存预后不良。
核心结论
- LA-HLH仍是临床挑战,需要专业化管理;及时诊断和适当的淋巴瘤特异性治疗对改善患者结局至关重要。
研究设计与样本
- 范围综述,检索PubMed(MEDLINE数据库),从595条搜索结果中纳入132篇文章,提供542例患者信息。
主要发现
- 患者中位年龄60岁(范围18-98),男性占62.7%。
- B细胞和T细胞非霍奇金淋巴瘤分别占45.6%和45.2%,霍奇金淋巴瘤占8.9%。
- 91.6%的患者为Ann-Arbor III-IV期,61.5%存在骨髓浸润。
- 可溶性CD25中位水平为10,000 U/ml,超过10,000 U/ml提示30天生存和总生存预后不良。
- 66.8%的患者在中位5.1个月后死亡。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hemophagocytic lymphohistiocytosis (HLH) is a severe hyperinflammatory syndrome driven by pathologic activation of cytotoxic T-lymphocytes and macrophages. Despite advances in diagnostics and management, adult patients with lymphoma-associated HLH (LA-HLH) harbor particularly poor prognosis and optimal treatment remains challenging. As systematic data on LA-HLH are scarce, we aimed to synthesize research evidence by thorough analysis of the published literature in PubMed (MEDLINE-database) within the context of a scoping review. Of 595 search results, 132 articles providing information on 542 patients were reviewed and analyzed. Median patient age was 60 years (range, 18-98) with male predominance (62.7%). B- and T-NHL were equally represented (45.6% and 45.2%), Hodgkin's lymphoma was reported in 8.9% of the cases. The majority of patients (91.6%) presented in Ann-Arbor-Stages III and IV, and bone marrow infiltration was observed in a significant proportion of patients (61.5%). Soluble CD25 levels were markedly elevated (median 10,000 U/ml), with levels beyond 10,000 U/ml indicating unfavorable prognosis for 30-day and overall survival. 66.8% of the patients died after median 5.1 months. LA-HLH remains a clinical challenge requiring specialized management. Timely diagnosis and appropriate lymphoma-specific treatment are of utmost importance to enhance patient outcomes.
引用
- Knauft J, Schenk T, Ernst T, et al. Lymphoma-associated hemophagocytic lymphohistiocytosis (LA-HLH): a scoping review unveils clinical and diagnostic patterns of a lymphoma subgroup with poor prognosis. Leukemia. 2024. PMID: 38238443. doi:10.1038/s41375-024-02135-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。